Cormorant Private Healthcare Fund III LP's Net Worth

$767 Million

Who is Cormorant Private Healthcare Fund III LP?

Cormorant Private Healthcare Fund III LP has an estimated net worth of $767 Million. This is based on reported shares across multiple companies, which include Prometheus Biosciences, Inc., Ambrx Biopharma, Inc., Design Therapeutics, Inc., Icosavax, Inc., Ventyx Biosciences, Inc., Tyra Biosciences, Inc., Monte Rosa Therapeutics, Inc., Verve Therapeutics, Inc., Immuneering Corp, Pyxis Oncology, Inc., Elevation Oncology, Inc., Ambrx Biopharma Inc., Biomea Fusion, Inc., Rain Therapeutics Inc., Olema Pharmaceuticals, Inc., and MoonLake Immunotherapeutics.

SEC CIK

Cormorant Private Healthcare Fund III LP's CIK is 0001817320

Past Insider Trading and Trends

2021 was Cormorant Private Healthcare Fund III LP's most active year for acquiring shares with 26 total transactions. Cormorant Private Healthcare Fund III LP's most active month to acquire stocks was the month of March. 2021 was Cormorant Private Healthcare Fund III LP's most active year for disposing of shares, totalling 14 transactions. Cormorant Private Healthcare Fund III LP's most active month to dispose stocks was the month of February. 2023 saw Cormorant Private Healthcare Fund III LP paying a total of $155,571,161.49 for 13,032,174 shares, this is the most they've acquired in one year. In 2021 Cormorant Private Healthcare Fund III LP cashed out on 15,787,341 shares for a total of $0.00, their largest year based on trade value.